Arcturus Therapeutics is trading 5.79% up at $14.79 as September 11, 2026 trading benefits from broad risk-on sentiment after August CPI matched forecasts.
- Major indexes are also higher, supporting a market-wide relief move rather than a clearly company-specific catalyst.
- Recent investor presentations highlighted upcoming Phase II OTC-deficiency data later in September.
- No new announcement directly explains the current advance.